Skip to main content

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Sharecare, Inc. (SHCR)

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Sharecare, Inc. (“Sharecare” or the “Company”) (NASDAQ: SHCR). The investigation concerns whether Sharecare and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

[Click here to learn more about the investigation]

On March 29, 2024, Sharecare disclosed that it had “identified a material weakness in our internal control over financial reporting” on December 31, 2023. Specifically, the Company did not maintain adequate internal controls with respect to its revenue recognition evaluation resulting from a change in services provided to a customer. On this news, the price of Sharecare shares declined by $0.22 per share, or approximately 28.39%, from $0.77 per share on March 28, 2024 to close at $0.55 on April 1, 2024.

If you purchased or otherwise acquired Sharecare securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.